Accendra Health updates its capital allocation strategy and CEO succession planning. The company also commented on its liquidity position and its plans for asset sales. Given current market conditions, Accendra Health has decided not to proceed with establishing an at-the-market issuance program. The decision is guided by the company’s current interests of stakeholders.
The proposed program would have allowed Accendra Health to issue modest amounts of equity opportunistically. The company planned to use the proceeds to reduce outstanding indebtedness. This included debt trading at discounts to par value. However, the program was never designed to provide liquidity for the company.
Therefore, Accendra Health does not expect the decision to affect its results of operations. The company also confirmed that published guidance remains unchanged. Meanwhile, the company continues to see improvement in cash collections. It has also made stronger progress in resolving payor collection issues.
As a result, management remains confident about its liquidity position. Accendra Health was undrawn on its $300 million revolving credit facility at the end of the second quarter. The company does not expect to rely on the facility regularly. Instead, it expects to use the facility only for occasional working capital fluctuations. Accendra Health remains focused on improving its balance sheet. The company also continues to prioritize leverage reduction.
Accendra Health Advances Non-Core Asset Sales
Accendra Health also provided an update on the planned sale of two non-core assets. The company is pursuing these transactions as part of its capital strategy. The first asset sale closed during the third quarter. Meanwhile, the company expects the second transaction to close before the end of the year.
Together, the two transactions are expected to generate approximately $45 million in cash. The cash injection will occur across the third and fourth quarters of the year. Furthermore, the transactions are expected to have a de minimis impact on Adjusted EBITDA. The company continues to use asset sales as an opportunistic capital management approach.
The transactions also support the company’s broader objective of strengthening its financial position. At the same time, Accendra Health continues to monitor market conditions. The company’s capital allocation approach remains focused on financial flexibility. Management also continues to evaluate opportunities that support balance sheet improvement.
CEO Succession Process Moves Toward 2026 Transition
Accendra Health also shared an update concerning its previously announced CEO succession plan. The company’s Board of Directors maintains a comprehensive and long-standing succession planning process.
The process receives support from leading executive search and advisory firms. Following Mr. Pesicka’s formal retirement announcement, the Board moved quickly. Mr. Pesicka announced his intention to retire by the end of 2026. Subsequently, the Board advanced the next phase of its succession process.
The Board has actively evaluated potential candidates as part of that process. It has also identified a strong pipeline of qualified candidates. These candidates have the experience and capabilities required for the company’s next phase of growth. Therefore, the Board currently expects to announce a successor by mid-September 2026.
This timing would allow Accendra Health to complete the leadership transition ahead of Mr. Pesicka’s anticipated retirement. This also buys the company more time to plan for an orderly transition. Mr. Pesicka will remain CEO until a replacement can be found. After the transition he will assume an advisory role. His continued involvement will support business continuity during the leadership handoff. It will also help ensure an orderly transition for the company and its stakeholders.
Explore Health Tech Insiders for the latest medical innovations and reliable strategic insights driving the future of technology-driven healthcare transformation.
News Source: Businesswire
